An Open Label, Randomised Study to Compare the Efficacy of Certolizumab Pegol (CZP) Plus a Dynamic or Fixed Dose Treatment Strategy in Patients With Rheumatoid Arthritis, a Phase II Study
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2016
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RICE
- 07 Jun 2017 Biomarkers information updated
- 11 Aug 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 11 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.